^
    13d
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Shanghai Virogin Biotech Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    14d
    One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=72, Not yet recruiting, Immorna Biotherapeutics, Inc. | Phase classification: P1 --> P1/2
    Phase classification
    14d
    Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=19, Completed, Immorna Biotherapeutics, Inc. | Recruiting --> Completed | N=156 --> 19
    Trial completion • Enrollment change
    20d
    CA101-001: A Study of DF6002 Alone and in Combination With Nivolumab (clinicaltrials.gov)
    P1, N=170, Completed, Dragonfly Therapeutics | Recruiting --> Completed | N=438 --> 170 | Trial completion date: Nov 2027 --> Nov 2025 | Trial primary completion date: Jan 2027 --> Nov 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Opdivo (nivolumab) • DF6002
    22d
    A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Beijing Bio-Targeting Therapeutics Technology Co., Ltd
    New P1 trial
    28d
    DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    rocakinogene sifuplasmid (INO-9012)
    1m
    KLS-3021, a multifunctional oncolytic virus, demonstrates potent early-intervention efficacy in preclinical models of prostate-confined and locally advanced prostate cancer. (PubMed, Front Oncol)
    Mice were randomized to receive vehicle, docetaxel, or KLS-3021, administered on day 9 (prostate-confined) or day 29 (visible/locally invasive) after implantation of luciferase-labeled PC-3 cells. Mechanistic analyses revealed extracellular matrix degradation, enhanced viral spread, increased immune cell infiltration, M1 macrophage polarization, and features of immunogenic cell death in KLS-3021-treated tumors. These results collectively demonstrate the translational potential of KLS-3021 as a minimally invasive or neoadjuvant therapeutic strategy for prostate cancer, especially in patients for whom early, localized intervention is medically feasible.
    Preclinical • Journal
    |
    PD-1 (Programmed cell death 1) • SPAM1 (Sperm Adhesion Molecule 1)
    |
    docetaxel
    1m
    Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings. (PubMed, Expert Opin Investig Drugs)
    IMNN-001 gene therapy could add clinically meaningful IL-12-driven immunotherapy to newly diagnosed ovarian cancer patients. IMNN-001 holds promise for synergistic combinations with immunotherapies requiring intrinsic immune activity.
    Review • Journal • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    IMNN-001
    1m
    Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Dec 2025 --> Dec 2026
    Trial initiation date
    1m
    INO 5401 Vaccination in BRCA1/2 Mutation Carriers (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Dec 2025 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    INO-5401 • rocakinogene sifuplasmid (INO-9012)
    2ms
    Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients (clinicaltrials.gov)
    P2, N=17, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed | Trial completion date: Jun 2028 --> May 2025
    Trial completion • Trial completion date
    |
    LDH elevation
    |
    Opdivo (nivolumab) • Tavo (tavokinogene telsaplasmid)
    2ms
    First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC. (PubMed, BMC Med)
    T3011 shows a favorable safety profile, immune-modulating effects, and preliminary efficacy in patients with advanced solid tumors.
    P1/2 data • Journal • First-in-human
    |
    CD8 (cluster of differentiation 8)
    |
    PD-L1 expression • PD-L1 negative
    |
    T3011